WallStreetZenWallStreetZen

NASDAQ: TVRD
Tvardi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TVRD

Based on 4 analysts offering 12 month price targets for Tvardi Therapeutics Inc

Min Forecast
$3.00+16.28%
Avg Forecast
$7.50+190.7%
Max Forecast
$15.00+481.4%

Should I buy or sell TVRD stock?

Based on 4 analysts offering ratings for Tvardi Therapeutics Inc.

Hold
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
1 analysts 25%

Be the first to know when Wall Street analysts revise their TVRD stock forecasts and price targets.

TVRD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-08
lockedlocked$00.00+00.00%2026-04-20
lockedlocked$00.00+00.00%2026-04-01
lockedlocked$00.00+00.00%2026-04-01

1 of 1

Forecast return on equity

Is TVRD forecast to generate an efficient return?

Company
-120.99%
Industry
94.92%
Market
176.46%
TVRD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TVRD forecast to generate an efficient return on assets?

Company
-67.98%
Industry
27.65%
TVRD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TVRD earnings per share forecast

What is TVRD's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$2.46
Avg 2 year Forecast
-$2.32
Avg 3 year Forecast
-$2.22

TVRD revenue forecast

What is TVRD's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

TVRD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TVRD$2.58$7.50+190.70%Hold
PLUR$2.25N/AN/A
BCTX$2.80N/AN/A
SKYE$0.71N/AN/A
NEUP$4.31N/AN/A
View Top Biotech Stocks

Tvardi Therapeutics Stock Forecast FAQ

Is Tvardi Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: TVRD) stock is to Hold TVRD stock.

Out of 4 analysts, 1 (25%) are recommending TVRD as a Strong Buy, 1 (25%) are recommending TVRD as a Buy, 1 (25%) are recommending TVRD as a Hold, 0 (0%) are recommending TVRD as a Sell, and 1 (25%) are recommending TVRD as a Strong Sell.

If you're new to stock investing, here's how to buy Tvardi Therapeutics stock.

What is TVRD's earnings growth forecast for 2026-2028?

(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.13%.

Tvardi Therapeutics's earnings in 2026 is -$15,439,000.On average, 10 Wall Street analysts forecast TVRD's earnings for 2026 to be -$23,082,797, with the lowest TVRD earnings forecast at -$28,684,397, and the highest TVRD earnings forecast at -$15,760,658. On average, 10 Wall Street analysts forecast TVRD's earnings for 2027 to be -$21,796,615, with the lowest TVRD earnings forecast at -$40,636,230, and the highest TVRD earnings forecast at -$5,516,230.

In 2028, TVRD is forecast to generate -$20,869,738 in earnings, with the lowest earnings forecast at -$42,631,642 and the highest earnings forecast at -$2,167,090.

What is TVRD's revenue growth forecast for 2026-2028?

(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.92%.

Tvardi Therapeutics's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast TVRD's revenue for 2026 to be $0, with the lowest TVRD revenue forecast at $0, and the highest TVRD revenue forecast at $0. On average, 10 Wall Street analysts forecast TVRD's revenue for 2027 to be $0, with the lowest TVRD revenue forecast at $0, and the highest TVRD revenue forecast at $0.

In 2028, TVRD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TVRD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TVRD) forecast ROA is -67.98%, which is lower than the forecast US Biotechnology industry average of 27.65%.

What is TVRD's Price Target?

According to 4 Wall Street analysts that have issued a 1 year TVRD price target, the average TVRD price target is $7.50, with the highest TVRD stock price forecast at $15.00 and the lowest TVRD stock price forecast at $3.00.

On average, Wall Street analysts predict that Tvardi Therapeutics's share price could reach $7.50 by Jun 8, 2027. The average Tvardi Therapeutics stock price prediction forecasts a potential upside of 190.7% from the current TVRD share price of $2.58.

What is TVRD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TVRD) Tvardi Therapeutics's current Earnings Per Share (EPS) is -$1.65. On average, analysts forecast that TVRD's EPS will be -$2.46 for 2026, with the lowest EPS forecast at -$3.06, and the highest EPS forecast at -$1.68. On average, analysts forecast that TVRD's EPS will be -$2.32 for 2027, with the lowest EPS forecast at -$4.33, and the highest EPS forecast at -$0.59. In 2028, TVRD's EPS is forecast to hit -$2.22 (min: -$4.54, max: -$0.23).

What is TVRD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TVRD) forecast ROE is -120.99%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.